RxDoctor Payments Data

Jonathan Powell

Medical Oncology · Baltimore, MDNPI 1629011432

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $10,500 of the $11,162 with a category attached, or 94.1%. 6 manufacturers reported payments, led by AstraZeneca at 56.1% of the total. Reporting peaked in 2019 at $7,079 and has fallen 98.8% since, to $83 in 2024.

$11,162in general payments, 2019–2025

Across 16 payments — averaging $697.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$6K
  • Shionogi Inc$4K
  • Vertex$500
  • Astrazeneca AB$266
  • AbbVie$83
  • E.r. Squibb & Sons, L.L.C.$52
$1,265,535in research payments, 2019–2025

Across 4 payments — averaging $316,384 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$1.3M

What the payments were for

  • Consulting fees$10,50094%
  • Travel & lodging$3123%
  • Food & beverage$3503%

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca7$6,261
Shionogi Inc1$4,000
Vertex1$500
Astrazeneca AB5$266
AbbVie1$83
E.r. Squibb & Sons, L.L.C.1$52

How this compares

$11,162 in reported general payments places this provider in the 60th percentile of 180 medical oncology providers in Maryland.

See all medical oncology providers in Maryland →

Other medical oncology in Baltimore

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →